BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34282745)

  • 1. Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports.
    Khoshnam-Rad N; Gheymati A; Jahangard-Rafsanjani Z
    Anticancer Drugs; 2022 Jan; 33(1):e1-e8. PubMed ID: 34282745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Induced Pyoderma Gangrenosum: A Review.
    Wang JY; French LE; Shear NH; Amiri A; Alavi A
    Am J Clin Dermatol; 2018 Feb; 19(1):67-77. PubMed ID: 28624960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.
    Wu BC; Patel ED; Ortega-Loayza AG
    Br J Dermatol; 2017 Jul; 177(1):72-83. PubMed ID: 27864925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
    Dasanu CA; Bockorny B; Alexandrescu DT
    J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of pyoderma gangrenosum induced by insulin.
    Noronha M; Arora S; Pai K; Sathish Pai B; Jindal A
    Int Wound J; 2019 Oct; 16(5):1239-1242. PubMed ID: 31353778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
    Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
    [No Abstract]   [Full Text] [Related]  

  • 7. Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis.
    Aggarwal P
    Dermatol Ther; 2020 Mar; 33(2):e13221. PubMed ID: 31925868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyoderma Gangrenosum Associated with Sunitinib: A Case Report.
    Sevimli Dikicier B
    Adv Skin Wound Care; 2019 Sep; 32(9):427-429. PubMed ID: 31408027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 10. Neutrophilic dermatoses: a review of current treatment options.
    Cohen PR
    Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyoderma gangrenosum after breast surgery: A systematic review.
    Ehrl DC; Heidekrueger PI; Broer PN
    J Plast Reconstr Aesthet Surg; 2018 Jul; 71(7):1023-1032. PubMed ID: 29748073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative Pyoderma Gangrenosum: A Clinical Review of Published Cases.
    Tolkachjov SN; Fahy AS; Cerci FB; Wetter DA; Cha SS; Camilleri MJ
    Mayo Clin Proc; 2016 Sep; 91(9):1267-79. PubMed ID: 27489052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the Literature [Formula: see text].
    Shavit E; Cecchini M; Limacher JJ; Walsh S; Wentworth A; Davis MDP; Alavi A
    J Cutan Med Surg; 2021; 25(4):371-376. PubMed ID: 33541119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy.
    Dixit S; Selva-Nayagam P; Hamann I; Fischer G
    J Low Genit Tract Dis; 2015 Jan; 19(1):e6-9. PubMed ID: 24769650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.
    Ben Abdallah H; Fogh K; Bech R
    Int Wound J; 2019 Apr; 16(2):511-521. PubMed ID: 30604927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia.
    Montoto S; Bosch F; Estrach T; Blade J; Nomdedeu B; Nontserrat E
    Leuk Lymphoma; 1998 Jun; 30(1-2):199-202. PubMed ID: 9669691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib induced pyoderma gangrenosum-like ulcerations.
    Akanay-Diesel S; Hoff NP; Kürle S; Haes J; Erhardt A; Häussinger D; Schulte KW; Bölke E; Matuschek C; Budach W; Gerber PA; Homey B
    Eur J Med Res; 2011 Nov; 16(11):491-4. PubMed ID: 22027642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genital pyoderma gangrenosum: report of two cases and published work review of Japanese cases.
    Satoh M; Yamamoto T
    J Dermatol; 2013 Oct; 40(10):840-3. PubMed ID: 24033392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological features and prognosis of pyoderma gangrenosum in Korea: A single centre, retrospective, observational study over 20 years.
    Kim YJ; Lee KH; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
    Indian J Dermatol Venereol Leprol; 2023; 89(1):25-34. PubMed ID: 35389018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.